Glycosylation-independent interaction with nivolumab indicates a broader application of nivolumab in management of multiple tumours especially considering that the intrinsic expression of PD-1 in tumour cells is usually accompanied with altered glycan modifications. The gene discussed is PDCD1; the disease is neoplasm.